+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Leukemia Drugs Market Research Reports

From
From
Copiktra - Product Thumbnail Image

Copiktra

  • Report
  • 26 Pages
From
Zanubrutinib - Product Thumbnail Image

Zanubrutinib

  • Report
  • 23 Pages
From
Kymriah - Product Thumbnail Image

Kymriah

  • Report
  • 38 Pages
From
Venclexta - Product Thumbnail Image

Venclexta

  • Report
  • 45 Pages
From
Zydelig - Product Thumbnail Image

Zydelig

  • Report
  • 29 Pages
From
Treanda/Bendeka - Product Thumbnail Image

Treanda/Bendeka

  • Report
  • 58 Pages
From
Rituxan - Product Thumbnail Image

Rituxan

  • Report
  • 82 Pages
From
Arzerra - Product Thumbnail Image

Arzerra

  • Report
  • 18 Pages
From
Imbruvica - Product Thumbnail Image

Imbruvica

  • Report
  • 51 Pages
From
Gazyva - Product Thumbnail Image

Gazyva

  • Report
  • 40 Pages
From
From
BCMA Targeted Therapies, 2017-2030 - Product Thumbnail Image

BCMA Targeted Therapies, 2017-2030

  • Report
  • 143 Pages
From
GLEEVEC Drug Profile, 2019 - Product Thumbnail Image

GLEEVEC Drug Profile, 2019

  • Report
  • 355 Pages
From
Loading Indicator

On average over 40,000 are diagnosed with leukemia each year in the United States. It is also one of the most common cancers in children. Large differences in therapeutic outcomes exist among patient groups such as children and old age sufferers, and according to the form of a disease that has many variants such as Acute (AML) and Chronic (CML) Myelocytic Leukemia, Acute (ALL) and Chronic (CLL) Lymphocytic Leukemia, and Hairy Cell Leukemia (HCL). These variations have led to unmet needs among specific patient groups. The selection of expert and insightful reports in this section enable you explore these market opportunities by providing key industry data such as drug development strategies, international market trends and forecasts and profiles of major players like Novartis, Pfizer and Bristol-Myers Squibb. Show Less Read more

adroll